Restorgenex Corporation (RESX) 0.7700 $RESX
RestorGenex to Present at Two Upcoming Growth Conferences
GlobeNewswire - Tue Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Sep 03, 5:29AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.
RestorGenex Reports Financial Results
GlobeNewswire - Wed Aug 12, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015.
RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
GlobeNewswire - Tue Jul 14, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.
SeeThruEquity Initiates Coverage on RestorGenex Corp. with a Price Target of $8.93
ACCESSWIRE - Wed Jul 08, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RestorGenex Corp. (OTCQX: RESX) with a price target of $8.93.
OTC Markets Group Welcomes RestorGenex to OTCQX
PR Newswire - Wed Jul 08, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
GlobeNewswire - Fri Jun 19, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.
RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
GlobeNewswire - Thu Jun 18, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings today, June 18, 2015. The company's common stock will continue to trade under the symbol "RESX".
RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Jun 16, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com.
Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
RestorGenex to Present at the Annual LD Micro Invitational Conference
GlobeNewswire - Mon Jun 01, 5:30AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5 Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.
RestorGenex Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models
GlobeNewswire - Thu May 21, 5:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Keith Ferguson, M.D. and Nathan Sandbo, M.D., both of the Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, presented scientific data utilizing RES-529 in idiopathic pulmonary fibrosis. The poster entitled "The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation" was presented on Tuesday, May 19, 2015 at the American Thoracic Society International Conference in Denver, Colorado.
RestorGenex to Present at Two Investor Conferences
GlobeNewswire - Wed May 20, 3:00PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.
A Deep Look At RestorGenex RES-440 For Acne
Jason Napodano, CFA - at Seeking Alpha - Thu May 14, 3:00PM CDT
RestorGenex Reports First Quarter 2015 Financial Results
GlobeNewswire - Mon May 11, 3:06PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its financial results and cash balance for the first quarter ended March 31, 2015.
RestorGenex Issues Annual Letter to Stockholders
GlobeNewswire - Thu Apr 23, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, is pleased to present its Annual Letter to Stockholders from CEO, Stephen M. Simes.
RES-529 Offers Two Shots On Goal For RestorGenex
Jason Napodano, CFA - Seeking Alpha - Tue Apr 07, 1:05PM CDT
By Jason Napodano, CFA and David Bautz, Ph.D RestorGenex ( OTCQB:RESX ) is a specialty pharmaceutical company developing treatments for ophthalmology, oncology, and dermatology. The company has two proprietary compounds under development, RES-529...
RestorGenex Reports Corporate Highlights and Financial Results for 2014
GlobeNewswire - Mon Apr 06, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, reported on its cash balance as of December 31, 2014 and its financial results for the year ended December 31, 2014. The Company also completed several significant milestones during 2014, including the following highlights:
RestorGenex to Present at the Future Leaders in the Biotech Industry Conference
GlobeNewswire - Wed Mar 18, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the 22 Annual Future Leaders in the Biotech Industry Conference, being held Friday, March 20, 2015, in New York, NY. Mr. Simes will provide a corporate overview at 9:00am ET. The presentation will be webcast and available at https://www.webcaster4.com/Webcast/Page/818/7620.
RestorGenex to Present at Two Upcoming Growth Conferences
GlobeNewswire - Tue Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Sep 03, 5:29AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.
RestorGenex Reports Financial Results
GlobeNewswire - Wed Aug 12, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015.
RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
GlobeNewswire - Tue Jul 14, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.
SeeThruEquity Initiates Coverage on RestorGenex Corp. with a Price Target of $8.93
ACCESSWIRE - Wed Jul 08, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RestorGenex Corp. (OTCQX: RESX) with a price target of $8.93.
OTC Markets Group Welcomes RestorGenex to OTCQX
PR Newswire - Wed Jul 08, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
GlobeNewswire - Fri Jun 19, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.
RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
GlobeNewswire - Thu Jun 18, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings today, June 18, 2015. The company's common stock will continue to trade under the symbol "RESX".
RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Jun 16, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com.
Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
RestorGenex to Present at the Annual LD Micro Invitational Conference
GlobeNewswire - Mon Jun 01, 5:30AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5 Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.
RestorGenex Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models
GlobeNewswire - Thu May 21, 5:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Keith Ferguson, M.D. and Nathan Sandbo, M.D., both of the Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, presented scientific data utilizing RES-529 in idiopathic pulmonary fibrosis. The poster entitled "The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation" was presented on Tuesday, May 19, 2015 at the American Thoracic Society International Conference in Denver, Colorado.
RestorGenex to Present at Two Investor Conferences
GlobeNewswire - Wed May 20, 3:00PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.
A Deep Look At RestorGenex RES-440 For Acne
Jason Napodano, CFA - at Seeking Alpha - Thu May 14, 3:00PM CDT
RestorGenex Reports First Quarter 2015 Financial Results
GlobeNewswire - Mon May 11, 3:06PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its financial results and cash balance for the first quarter ended March 31, 2015.
RestorGenex Issues Annual Letter to Stockholders
GlobeNewswire - Thu Apr 23, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, is pleased to present its Annual Letter to Stockholders from CEO, Stephen M. Simes.
RES-529 Offers Two Shots On Goal For RestorGenex
Jason Napodano, CFA - Seeking Alpha - Tue Apr 07, 1:05PM CDT
By Jason Napodano, CFA and David Bautz, Ph.D RestorGenex ( OTCQB:RESX ) is a specialty pharmaceutical company developing treatments for ophthalmology, oncology, and dermatology. The company has two proprietary compounds under development, RES-529...
RestorGenex Reports Corporate Highlights and Financial Results for 2014
GlobeNewswire - Mon Apr 06, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, reported on its cash balance as of December 31, 2014 and its financial results for the year ended December 31, 2014. The Company also completed several significant milestones during 2014, including the following highlights:
RestorGenex to Present at the Future Leaders in the Biotech Industry Conference
GlobeNewswire - Wed Mar 18, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the 22 Annual Future Leaders in the Biotech Industry Conference, being held Friday, March 20, 2015, in New York, NY. Mr. Simes will provide a corporate overview at 9:00am ET. The presentation will be webcast and available at https://www.webcaster4.com/Webcast/Page/818/7620.
